Erik Müürsepp


Erik is an associate in the Commercial IP/IT team and advises clients on a range of commercial matters. His experience includes negotiating licensing and research and collaboration agreements, litigation settlement agreements and advising on the IP aspects of corporate transactions. Erik has also advised on large outsourcing deals, software licensing and IT services agreements.

Erik works with clients across a number of industries, with a particular focus on the life sciences and technology sectors. Erik’s interest in providing commercial advice to life sciences companies is complemented by his background in biochemistry.

Erik joined Bristows as a trainee solicitor in August 2016 and as part of his training contract gained experience in a range of practice areas, including contentious and transactional intellectual property, corporate, brands and real estate. Erik also spent three months on secondment at the technology transfer office of a leading London university, gaining valuable experience and insight into the commercialisation of world-class scientific research.


  • BSc, Biochemistry, University of Bristol
  • MRes, Molecular Biophysics, King’s College London
  • Qualified 2018

What others say

“Bristows was a valued partner in the success of making our vision become a reality.” Stephanie Morris, Director of Industry Partnerships and Commercialisation at Imperial College London
“They enabled a very positive conclusion to the overall deal.” Richard Fagan, Director of BioPharma at UCL Business
“Their expertise made them the perfect partner to work with on the highly complex Apollo transaction.” Richard Fagan, Director of BioPharma at UCL Business
“UCLB has worked with Bristows for over 25 years, in relation to intellectual property licensing transactions as well as corporate transactions such as spinout formation.” Richard Fagan, Director of BioPharma at UCL Business
“Bristows’ knowledge of the life sciences market and players, as well as their licensing expertise, was invaluable as we navigated this complex transaction.” Iain Thomas, Cambridge Enterprise’s Head of Life Sciences

Related Articles